Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03843528 |
Recruitment Status :
Recruiting
First Posted : February 18, 2019
Last Update Posted : September 9, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myeloid Leukemia Myelodysplastic Syndromes Mixed Phenotype Acute Leukemia Juvenile Myelomonocytic Leukemia | Drug: Vorinostat Drug: Azacitidine Injection | Phase 1 |
Children and adolescents ages 1 to 21 years of age who are undergoing allogeneic hematopoietic cell transplantation for a myeloid malignancy (AML, MDS, JMML, MPAL) will be eligible. There are no restrictions on donor type, conditioning, stem cell source, of GVHD prophylaxis approach.
All participants will be treated on a single arm, and will initially receive 2 cycles of standard post-transplant azacitidine at a dose of 32mg/m2/dose IV/subcutnaeous for 5 days, in 28 day cycles. This is considered standard of care.
After tolerance of 2 cycles of azacitidine has been established, patients will be assigned to receive vorinostat orally at different dose levels, depending on the stage of the study. The dose level assignments will be conducted on a standard 3+3 design, whereby dose-escalation is peformed if previous patients tolerated the dose without dose-limiting toxicities, and dose-reduction is performed if dose-limiting toxicities are seen. The starting dose will be 100mg/m2/dose on days 1-7 and 15-21 of each 28 day cycles. This will be in addition to receiving azacitidine at the fixed dose above. In order to start each cycle, participants will be required to meet specific clinical parameters to ensure safety.
The dose of vorinostat between patients will be escalated or de-escalated until criteria for finding the maximum tolerated dose (MTD) is reached, and this will complete the study. Participants will continue to receive the prescribed dose of vorinostat for up to 7 cycles (9 total cycles of azacitidine).
Participants are followed for dose-limiting toxicities primarily during the first two course of combined therapy (cycles 3 and 4), but are continued to be tracked until the completion of all potential combined treatment (1 year or 7 combined cycles, whichever is earlier).
Principal aims:
1. To evaluate the maximum tolerated dose (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for childhood myeloid malignancies.
Secondary aims:
- To describe the dose-limiting toxicities (DLT) of the vorinostat used in combination with low-dose azacitidine.
- To describe rates of relapse, transplant related mortality, graft-versus-host disease, and overall survival.
- To describe the effect of epigenetic modification on lymphocyte reconstitution in the post-alloHCT setting.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | 3+3 dose-escalation study |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies |
Actual Study Start Date : | May 1, 2019 |
Estimated Primary Completion Date : | May 1, 2021 |
Estimated Study Completion Date : | December 31, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Combined therapy
Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design. Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle. |
Drug: Vorinostat
Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication. Drug: Azacitidine Injection Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation. |
- Maximum tolerated dose (MTD) [ Time Frame: 4 months ]The primary outcome of this study is to determine the MTD of vorinostat in combination with low-dose azacitidine, using dose-escalation methodology. This is based on toxicities developed by participants enrolled on the study.
- Dose-limiting toxicities [ Time Frame: 4 months ]Rates of side effects from vorinostat will be recorded and described.
- GVHD [ Time Frame: 1 year ]Incidence of GVHD will be recorded and described.
- Relapse [ Time Frame: 1 year ]Incidence of relapse will be recorded and described
- Survival [ Time Frame: 1 year ]Duration of survival will be recorded and described
- Immune recovery [ Time Frame: 1 year ]Immune profile will be measured monthly for the first year post-transplant.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is 1 year to 21 years of age.
- Patient has a diagnosis of AML, MDS, MDS/AML, MPAL, or JMML. Note: patients are allowed to have received a HMA or HDACi prior to undergoing alloHCT.
- Patient has undergone allogeneic hematopoietic cell transplantation (no restrictions on conditioning regimen, donor or stem cell source, or GVHD prophylaxis regimen).
- Patient and/or parent(s) or legal guardian(s) are capable of understanding the study, including potential benefits and risks, and sign written informed consent. Age-appropriate assent will be obtained.
- Female patient of childbearing potential has a negative screening pregnancy test (urine or serum, as per local institutional standard).
- Female patient with infant(s) agrees not to breastfeed her infant(s) while on study.
- Patient of child-bearing potential (male and female) agrees to use effective method of contraception during the study.
Exclusion Criteria:
- Patient is enrolled on a clinical trial with investigational post-transplant medications. Note: trials involving defibrotide and post-transplant cyclophosphamide are permitted.
- Patient has a planned administration of non-protocol chemotherapy, radiation therapy, donor leukocyte infusion, or immunotherapy during the planned study period.
- Patient has a known allergy to azacitidine or vorinostat.
- Patient has chronic myelogenous leukemia.
-
Concomitant use of coumarin-derived anticoagulants or valproic acid.
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03843528
Contact: Benjamin Oshrine, MD | 727-460-9921 | benjamin.oshrine@jhmi.edu |
United States, Florida | |
UF Health Shands Children's Hospital | Not yet recruiting |
Gainesville, Florida, United States, 32610 | |
Contact: Gigi Moore-Higgs mooregj@ufl.edu | |
Principal Investigator: Paul Castillo Caro, MD | |
Johns Hopkins All Children's Hospital | Recruiting |
Saint Petersburg, Florida, United States, 33701 | |
Contact: Benjamin Oshrine, MD boshrin1@jhmi.edu |
Principal Investigator: | Benjamin Oshrine, MD | Johns Hopkins All Children's Hospital |
Responsible Party: | Benjamin Oshrine, Physician, Bone Marrow Transplant, Johns Hopkins All Children's Hospital |
ClinicalTrials.gov Identifier: | NCT03843528 |
Other Study ID Numbers: |
IRB00202540 |
First Posted: | February 18, 2019 Key Record Dates |
Last Update Posted: | September 9, 2020 |
Last Verified: | September 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Leukemia Leukemia, Myelomonocytic, Juvenile Myelodysplastic Syndromes Neoplasms by Histologic Type Neoplasms Leukemia, Myeloid Bone Marrow Diseases Hematologic Diseases Myelodysplastic-Myeloproliferative Diseases |
Azacitidine Vorinostat Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors Histone Deacetylase Inhibitors |